ARWR

NASDAQ · Biotechnology

Arrowhead Pharmaceuticals In

Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks

$72.69

-5.26 (-6.75%)

As of May 9, 9:34 PM ET ·

ARWR News1 articles

Arrowhead Sees Volatility After S&P MidCap 400 Inclusion, Goldman Eyes 2026 Pipeline

Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.